Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 11/20 | 0.61 |
| ▸ | LTB4R | Q15722 | 4/20 | 0.61 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.41 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3679305 | 0.93 | PLA2G4A (0.61) | PLA2G4ALTB4R | |
| SCHEMBL13767685 | 0.93 | PLA2G4A (0.55) | PLA2G4ALTB4RCYSLTR2CYSLTR1 | |
| SCHEMBL13767647 | 0.88 | PLA2G4A (0.54) | PLA2G4ALTB4R | |
| SCHEMBL9117646 | 0.86 | PLA2G4A (0.73) | PLA2G4ALTB4RCYSLTR2CYSLTR1 | |
| SCHEMBL10562872 | 0.86 | PLA2G4A (0.60) | PLA2G4ALTB4RCYSLTR2CYSLTR1F2 | |
| SCHEMBL13767658 | 0.84 | PLA2G4A (0.59) | PLA2G4ALTB4R | |
| SCHEMBL28392455 | 0.84 | PLA2G4A (0.58) | PLA2G4ALTB4R | |
| SCHEMBL8951394 | 0.83 | PLA2G4A (0.56) | PLA2G4ALTB4RCYSLTR2CYSLTR1F2 | |
| SCHEMBL8532687 | 0.81 | CPT2 (0.53) | — | |
| SCHEMBL9226275 | 0.81 | PLA2G4A (0.55) | PLA2G4ALTB4RCYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090191183-A1 | SUBSTITUTED INDOLES | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090191183-A1 | SUBSTITUTED INDOLES | CYSLTR1, LTB4R, LTB4R2 | PLA2G4A 144/4885LTB4R 2/4885CYSLTR2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.